skip to Main Content

FDA Grants Orphan Drug Designation to APX005M for Three Cancer Types

Newsfeed image, light gray text on dark gray background

APX005M (Apexigen) is a humanized monoclonal antibody that targets CD40. The agent is being evaluated in combination with chemotherapy, radiation, immunotherapy or a cancer vaccine for treatment of several malignancies, including esophageal, gastroesophageal junction and pancreatic cancers, as well as melanoma, non-small cell lung cancer, rectal cancer and sarcoma.Read more . . . 

Back To Top